Campto - Irinotecan Injection

CAMPTO is indicated for the treatment of patients with advanced colorectal cancer:

• In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease,
• As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.

CAMPTO in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum.

Campto in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.